Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2026/11/13

The company discloses its corporate governance structure and a skills matrix for its directors and executive officers. The report does not state any specific changes from the previous report.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors10 (including 4 outside directors)
Committee5
Nomination and Compensation CommitteeAudit & Supervisory CommitteeRisk Management CommitteeCompliance Committeeand Sustainability Committee. The proportion of outside members of each committee is 非開示
Changes this time

No changes from the previous report are described.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors10 (including 4 outside directors)
CommitteeNomination and Compensation Committee (name: Nomination and Compensation Committee; proportion of outside members: Not disclosed), Audit & Supervisory Committee, Risk Management Committee, Compliance Committee, and Sustainability Committee. The proportion of outside members of each committee is Not disclosed
Changes this timeNo changes from the previous report are described.
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This disclosure is intended to show the governance structure, each individual’s strengths, and their relevance to the business. The reasons for the changes from the previous report are not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/11/13 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori